Geoffrey Maltzahn is the founder of Tessera Therapeutics. Tessera Therapeutics has raised $300M in total funding. Latest round: Series C.
Geoffrey von Maltzahn is co-founder and board chair of Tessera Therapeutics, as well as a general partner at Flagship Pioneering, which he joined in 2009. He has co-founded multiple companies, including Tessera Therapeutics, where he led the development of its Gene Writing™ technology. He has also served as founding chief executive officer of several Flagship companies and has deep expertise in genome engineering, the microbiome, bioengineering, and nanotechnology.
Full founder directory · Investor directory · Company funding database · Fundraising library